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Introduction
Melatonin is a small indolamine principally produced in 
vertebrates by the pineal gland and released in the bloodstream. 
Melatonin shows a sharp peak of secretion at night, delivering 
the circadian message to the organism. In humans, it has several 
mechanisms of action, through its binding to G protein coupled 
melatonin receptors including circadian rhythm control, sleep 
cycle and many aspects of cancer inhibition. Melatonin also 
exerts receptor-independent functions, such as detoxification 
of free radicals, protecting key molecules from oxidative stress 
under conditions of ischemia, drug toxicity or ionizing radiation 
[1].
Melatonin interferes with cancer at all the phases of the 
illness: initiation, progression and spreading from the primary 
focus. Surprisingly, many molecular mechanisms have been 
proposed to explain its inhibitory actions [2]. Initially, most 
of the studies addressing the oncostatic actions of melatonin 
were performed in animal models undergoing chemically-
induced mammary tumors and also in estrogen responsive 
human breast cancer cell lines. In this particular case, the anti-
proliferative effect of the pineal hormone can be explained in 
terms of estrogen synthesis inhibition and interference with the 
estrogen-signaling pathways since melatonin has both SERM 
(selective estrogen receptor modulator) and SEEM (selective 
estrogen enzyme modulator) properties [3].
The value of melatonin as an adjuvant molecule to be 
combined with either chemotherapy or radiotherapy has 
been tested in cancer patients dealing with solid tumors at 
advanced stages of disease. The main conclusion was that this 
indoleamine restrains tumor development and growth, shows 
significant improvements in tumor remission, 1 and 5 years 
survival and importantly, ameliorates the undesirable side 
effects consequence of chemotherapy and radiotherapy [4,5]. In 
 
the past few years, the number of published articles supporting 
the oncostatic role of melatonin on experimental models of a 
variety of cancers is growing exponentially [6]. Many hormone-
independent cancer types, such as leukemia, glioblastoma, 
ovarian, prostate, gastric, esophageal, colon, pancreas, hepatic 
and lung cancers have been shown to be susceptible to inhibition 
by melatonin when the pineal hormone is administered either 
alone or combined with either radiotherapy or chemotherapy. 
Practically all the results reported have been positive, and 
melatonin has been described as an inhibitor of tumor growth 
under both in vitro and in vivo experimental conditions. 
Melatonin has anti-proliferative actions in ovarian [7], prostate 
[8], gastric [9], colon [10], pancreatic [11], hepatic [12], lung 
[13], leukemia [14] and glioblastoma cancers [15]. Several 
mechanisms of action of melatonin have been proposed to 
explain how the pineal hormone achieves its anti-cancer effects. 
Among them, the most important are: modulation of signaling 
transduction pathways triggered by melatonin binding to the 
MT-1 and MT-2 cell membrane receptors, expressed in many 
normal tissues and cancer cells [16]. Melatonin also exerts anti-
oxidant effects, controlling the production of reactive oxygen 
species modulating the intracellular free radical stress and 
therefore determining the progression of the tumor. For example, 
it has been described that melatonin, through its role as a direct 
scavenger of radical oxygen and nitrogen species (ROS and 
RNS) and also through activation of antioxidant enzymes, can 
effectively protect the pancreatic tissue against oxidative stress 
and inflammatory damage [11]. The protective role of melatonin 
as an anti-oxidant agent has been characterized in detail in 
other cancer types. Thus, in H4IIE hepatoma cells, H2O2-induced 
activation of the extracellular signal-regulated protein kinases 
ERK1/2 and p38 MAPK, and some of their downstream protein 
effectors, were strongly weakened by melatonin, as well as H2O2-
induced phosphorylation of Akt and the Akt substrate mTOR, 
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and eIF4E-binding protein 1 (4E-BP1), mainly via preventing 
Ras activation. The main conclusion was that melatonin is able to 
triggered different protective mechanisms against ROS induced 
damage in hepatoma cells, preventing many of the H2O2-induced 
alterations in the MAPK and mTOR signaling pathways through 
inhibition of Ras [17].
Tumor angiogenesis, the formation of new vessels from 
preexisting vasculature in conditions of hypoxia, supports 
expansion of the tumor mass and is an event essential during 
progression of cancer. The value of melatonin as an antiagiogenic 
molecule has been demonstrated in several models. In 
hepatocarcinoma HepG2 cells, melatonin at pharmacological 
concentrations induced a decrease in the secreted levels of 
VEGF, and also prevented HUVEC (endothelial cells) tube 
formation under hypoxia. Prevention of tube formation seems to 
be associated with a down-regulation of the hypoxia inducible 
factor HIF-1α [18]. The inhibition of angiogenesis by melatonin 
has also been described in animal models. In nude mice bearing 
gastric tumors, melatonin treatment reduced the expression 
of the melatonin nuclear receptor RZR/RORγ, SUMO-specific 
protease 1, HIF-1α and VEGF at transcriptional and translational 
levels [9].
Escape from apoptosis plays a crucial role in cancer 
progression. The anti apoptotic properties of melatonin have 
been reported in all the cancer types mentioned above [6]. 
The molecular changes triggered by the pineal hormone are 
similar; thus, melatonin positively regulates the expression of 
p53 and p21, Bax, Bad, caspases 3, 7 and 9, cyclin D1, and down-
regulates the expression of anti-apoptotic proteins such as Bcl-2 
or surviving and XIAP. For example, in human hepatocarcinoma 
HepG2 and SMMC-7721 cells, cIAP-1, survivin and XIAP, were 
related to the co-expression of COX-2. Melatonin decreased COX-
2 expression and prevented Akt activation. These results indicate 
that melatonin overcomes apoptosis resistance via the COX-2/
PI3K/AKT pathway [12,19]. Melatonin can also potentiate the 
apoptotic properties of diverse chemotherapeutic compounds. 
A study in hepato carcinoma cells demonstrated that melatonin 
synergistically augmented sorafenib-induced apoptosis, and this 
result is dependent on the activation of caspase-3 and the JNK/c-
jun pathway [20]. 
Local invasion, the first stage prior to the development of 
secondary tumors or metastases is another aspect of cancer 
progression that can be regulated by melatonin. The pineal 
hormone exhibits anti-invasive and anti-metastatic properties 
in a variety of tumors by suppressing the enzymatic activity 
of MMP-9. In HepG2 cells, pharmacological concentrations of 
melatonin impaired MMP-9 gelatinase activity and effectively 
blocked cell invasion and motility through a simultaneous down 
regulation of MMP-9 gene expression and up regulation of the 
MMP-9-specific inhibitor metalloproteinase (TIMP)-1 [21]. 
A part from all the effects in cancer cell proliferation, 
apoptosis, angiogenesis, invasion, it is becoming clear that 
melatonin co-administration improves the sensitivity of cancers 
to inhibition by conventional chemotherapeutic agents. One 
of the most striking recent findings described, concerning 
melatonin´s anti-cancer activity is its ability to transform 
cancers that are totally resistant to chemotherapeutic drugs to 
a sensitive to chemotherapy state. Thus, it has been recently 
reported that incubation with melatonin resulted in a marked 
increase in the cytotoxicity of clofarabine in leukemic resistant 
cells. Melatonin treatment induced higher levels of acetylation, 
which suggest that melatonin alters DNA accessibility via 
histone acetylation and relaxation of the chromatin structure, 
which could allow clofarabine to target the DNA more efficiently. 
The molecular mechanisms of clofarabine resistance probably 
include an ABCG2 over expression simultaneous to a decreased 
expression of dCKgene with methylated promoter regions. No 
changes in ABCG2 expression or any changes in methylation 
status in clofarabine-resistant cells where identified. However, 
acetylation of histone increases gene expression, which is known 
to be an epigenetic mechanism. This is the first report to find 
that histone deacetylation of the dCK promoter is responsible 
for the decreased expression of dCK in clofarabine-resistant 
leukemic cells [22]. As mentioned above, melatonin overcomes 
apoptosis resistance in hepatocarcinoma cells via the COX-2/
PI3K/AKT pathway [12]. In several pancreatic tumor cell lines 
(AsPc-1, MiaPaCa-2 and Panc-28) and nude mice with pancreatic 
tumors bearing xenografts, melatonin enhanced the effects of 
gemcitabine on cell proliferation and invasion, action that was 
independent of melatonin membrane receptors. Mice treated 
simultaneously with both agents have greater reductions in 
tumor size compared to animals treated only with gemcitabine. 
The effect of melatonin seems to take account through a 
suppression of IKB-phosphorylation, which in turn results in 
an inhibition of NF-kB. Genes that respond to NF-kB show lover 
levels of expression and these molecular changes seem to reverse 
gemcitabine resistance in pancreatic tumors [23].
Conclusion
In summary, melatonin, through a variety of MT1 and MT2 
dependent mechanisms, and melatonin receptor independent 
mechanisms, impairs cancer development and growth. It has 
become clear that melatonin exerts anti-proliferative actions, 
not only in hormone-dependent tumors, but also in practically all 
the tumors that have been tested. The anti-proliferative actions 
are accompanied by an apoptotic effect of the pineal hormone. 
Melatonin causes a delay in the cell cycle progression, restrains 
cancer invasion and inhibits signaling pathways leading to 
metastases. In agreement with this, it has been demonstrated for 
many kind of cancers that melatonin has anti-angiogenic effects. 
Finally, melatonin renders cancers resistant to chemotherapeutic 
agents to treatment sensitive, and enhances the cytotoxicity 
of most of the chemo drugs tested. The molecular targets up 
or down-regulated by melatonin participate in a variety or 
mechanisms and are similar in most of the tumor studied. Among 
them, there are cell cycle controllers, such as p21, p53 and cyclins; 
apoptosis regulators (Bcl2, Bax, Bad, surviving) and effectors 
(caspases 3, 7 and 9); kinases such as AKT or ERK; transcription 
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factors (NF-kB) metalloproteinase (MMP9); cytokines (IL6, TNF 
α) and proteins implicated in angiogenesis such as VEGF. For all 
the reasons pointed above, melatonin is a molecule with a great 
potential to be considered in cancer therapy.
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